EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

On April 13, 2018, EyeGate Pharmaceuticals, Inc. (“the “Company”), announced the pricing of a public offering of up to 14,730,000shares of its common stock, 6,536.4 shares of its Series C Convertible Preferred Stock (the “Preferred Stock”) and warrants exercisable for up to 35,156,250 shares of its common stock in a best efforts registered public offering (the “Offering”) at a combined purchase price of $0.32 per share of common stock (or common stock equivalent) and warrant. The gross proceeds of the offering are expected to be approximately $11.25 million. The Offering is expected to close on April 17, 2018.

The Preferred Stock has a purchase price of $1,000 per share is convertible at any time into an aggregate of 20,426,250 shares of common stock at an initial conversion price of $0.32 per share, subject to certain ownership limitations. The Preferred Stock is only entitled to dividends in the event dividends are paid on the Company's shares of common stock and will not have any preferences over the Company's shares of common stock or any voting rights, except for limited circumstances. The rights, preferences and privileges of the Preferred Stock will be set forth in a Certificate of Designation of Preferences, Rights and Limitations of Preferred Stock (the “Certificate of Designation”), which the Company will file with the Delaware Secretary of State prior to the closing of the Offering. A holder of Preferred Stock will be prohibited from converting shares Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the shares of the Company’s common stock then issued and outstanding, which may be increased to 9.99% in certain circumstances.

The warrants will be immediately exercisable, will expire five years from issuance and will have an exercise price of $0.32 per share. The number of shares issuable upon exercise of the warrants and the exercise price of the warrants are adjustable in the event of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. A holder of warrants will not have the right to exercise any portion of the warrant if the holder would beneficially own in excess of 4.99% of the shares of the Company’s common stock outstanding immediately after giving effect to such exercise. This percentage may, however, be raised or lowered to an amount not to exceed 9.99% at the option of the holder upon at least 61 days’ prior notice from the holder to the Company, and holders may elect to receive warrants with a beneficial ownership limitation of 9.99%.

In connection with the Offering, the Company entered into a Securities Purchase Agreement (“Securities Purchase Agreement”) with certain of the investors in the Offering and also engaged H.C. Wainwright & Co., LLC (the “Placement Agent”) to act as exclusive placement agent for the Offering. The Company agreed to pay the Placement Agent a cash placement fee equal to 7.0% of the gross proceeds from the Offering, a management fee equal to 0.5% of the gross proceeds from the Offering, plus (i) a non-accountable expense allowance of $25,000 and (ii) reimbursement for legal fees and expenses of up to $100,000.

The net proceeds to the Company from the Offering, after deducting the Placement Agent’s fees and expenses, the Company’s estimated offering expenses, and excluding the proceeds, if any, from the exercise of the warrants issued in the Offering, are expected to be approximately $10.1 million. The Company currently intends to use the net proceeds from the Offering, together with other available funds, to support its operations, including for clinical trials, for working capital and for other general corporate purposes, which will include the pursuit of its other research and development efforts and could also include the acquisition or in-license of other products, product candidates or technologies, though no such acquisition or in-license is current contemplated.

A registration statement, as amended, relating to these securities (File No. 333-223887) was declared effective by the Securities and Exchange Commission (“SEC”) on April 12, 2018. The Offering was made only by means of a prospectus forming a part of the effective registration statement.

The descriptions of terms and conditions of each of the form of Securities Purchase Agreement, the form of Certificate of Designation relating to the Series C Convertible Preferred Stock and form of Warrant set forth herein do not purport to be complete and are qualified in their entirety by the full text of the form of Securities Purchase Agreement, the form of Certificate of Designation and form of Warrant, which are attached hereto as Exhibit 10.1, Exhibit 3.1 and Exhibit 4.1, respectively, and incorporated herein by reference.

The Securities Purchase Agreement contains representations and warranties that the parties made to, and solely for the benefit of, the other in the context of all of the terms and conditions of that agreement and in the context of the specific relationship between the parties.

On April 13, 2018, the Company issued a press release regarding the transactions described above under Item 1.01 of this Current Report on Form8-K.A copy of the press release is attached hereto as Exhibit99.1 and is incorporated herein by reference.

(d) Exhibits.

EYEGATE PHARMACEUTICALS INC Exhibit
EX-3.1 2 tv491024_ex3-1.htm EXHIBIT 3.1   Exhibit 3.1   EYEGATE PHARMACEUTICALS,…
To view the full exhibit click here

About EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG)

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.